EBIT Guidance Upgrade
Fresenius raised its full-year EBIT growth guidance from 3%-7% to 4%-8%, reflecting successful execution of its strategy and strong momentum.
Strong Core EPS Growth
Core EPS grew by an impressive 14%, significantly outpacing top-line growth, highlighting effective cost management and operational execution.
Kabi's Performance
Kabi achieved an excellent 16.7% EBIT margin with strong contributions from newly launched products and pipeline progress, particularly in IV generics and biosimilars.
Biopharma Growth
Biopharma reported a 37% organic growth with strong market traction, and achieved key milestones such as FDA interchangeability designation for denosumab.
Strong Cash Flow
Operating cash flow reached EUR 2.2 billion, supporting the company's deleveraging efforts and capital allocation framework.